Clinical Neuropsychopharmacology and Therapeutics
Online ISSN : 1884-8826
Current issue
Showing 1-6 articles out of 6 articles from the selected issue
Letter to the Editor
Brief Report
  • Akifumi Nakamura, Kazuo Mihara, Goyo Nagai, Noboru Sakumoto, Tsuyoshi ...
    2018 Volume 9 Pages 3-6
    Published: March 14, 2018
    Released: March 14, 2018

    Purpose: Marked elevations of serum creatine kinase (CK) activity in schizophrenia treated with atypical antipsychotics is regarded as a sign of neuroleptic malignant syndrome or rhabdomyolysis. It is suggested that atypical antipsychotics antagonize the 5-HT2A receptor in skeletal muscle, leading to changes in the sarcolemma which increases its permeability to CK. The 5-HT2A receptor gene (HTR2A) contains the T102C and His452Tyr polymorphisms, both of which affect the 5-HT2A receptor function. Meanwhile, the cytochromeP450 2D6 (CYP2D6), which shows a genetic polymorphism, may be involved in the development of CK elevation, because most antipsychotics are predominantly metabolized by this enzyme. This study aimed to investigate the relationship between the occurrence of CK elevation by atypical antipsychotics and these polymorphisms.

    Methods: The subjects were 15 Japanese schizophrenic patients who had developed CK elevation during the administration of atypical antipsychotics. The HTR2A T102C and His452Tyr, and CYP2D6 polymorphisms were determined by the polymerase chain reaction methods.

    Results: The allele frequencies of these polymorphisms were as follows: 102T, 40% vs. 102C=60%; His452, 100% vs. 452Tyr=0%; wild type for CYP2D6, 77% vs. *10=13% vs. *5=10%, respectively. Genotype patterns and allele frequency were nonspecific.

    Conclusions: These findings suggest that these genetic polymorphisms are not related to the development of CK elevation by atypical antipsychotics.

    Download PDF (71K)
Case Report